✍️ Reporter Jang Ji-young, Asia Today
| Concurrent growth in performance and business scale through full-lifecycle digitalization of clinical trials
JNPMEDI is continuing its growth trend by prioritizing a digital transformation strategy that covers the entire clinical trial process. The company is evaluated as expanding both its performance and business scale by establishing a business model that integrates clinical operations, data management, and global regulatory response into a single structure.
According to industry sources on the 28th, JNPMEDI's sales last year increased approximately 2.5 times compared to the previous year. Based on this trend, the company expects to maintain a high growth rate this year as well. Industry analysis suggests that the business structure itself has entered an expansion phase due to accumulated demand for the digital transformation of clinical trials, rather than the effect of a single project expansion or one-time orders.
Unlike existing contract research organizations (CROs) or simple clinical IT companies, JNPMEDI has built a structure that manages the entire clinical trial process as a single digital flow. The linking of the entire lifecycle—from the clinical trial planning stage to operation, data management, and response to regulatory submissions—is cited as a key differentiator. The company explained that it focused on structurally reducing the administrative burden and data management inefficiencies that repeatedly occur at clinical sites.
Its flagship solution, 'Maven Clinical Cloud,' focused on improving the limitations of data omission, error, and change history management that occurred in existing clinical trial environments that relied on paper documents and manual transcription. By applying electronic recording and management from the data generation stage and designing it to systematically track change history, it simultaneously increased data reliability and management efficiency.
Automation functions applied to the clinical trial process are also contributing to improved operational efficiency. By automatically designing data structures and consistently applying management rules based on clinical trial protocol standards, the company has reduced errors that may occur at the design stage and alleviated the burden of repetitive tasks. As a result, it is reported that cost reduction and the effect of shortening the clinical trial duration are appearing simultaneously.
Global regulatory response capability is also mentioned as a major competitive edge. The company has advanced its solutions by reflecting the data standards and submission requirements demanded by major regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Ministry of Food and Drug Safety (MFDS). In addition, it is expanding its scope of application in multi-national clinical trial environments by designing clinical data to be managed and converted in accordance with international standards.
An industry official stated, "In the global clinical trial environment, data management capabilities and regulatory response abilities are required simultaneously. There is a growing trend to attempt to integrate clinical operations, data, and regulatory response into a single platform."
Based on this business structure, JNPMEDI is accelerating its move into the global market. In particular, it plans to gradually increase the proportion of overseas projects by combining regulatory response consulting and clinical operation support, centered on the United States. The plan is to build a foundation for mid- to long-term growth by accumulating operational experience in markets with strict regulatory requirements.
A company official said, "The clinical trial environment is rapidly reorganizing around data and regulatory response. We will continue to improve the operational efficiency of domestic and international clinical sites through our integrated platform."
✍️ Reporter Jang Ji-young, Asia Today
| Concurrent growth in performance and business scale through full-lifecycle digitalization of clinical trials
JNPMEDI is continuing its growth trend by prioritizing a digital transformation strategy that covers the entire clinical trial process. The company is evaluated as expanding both its performance and business scale by establishing a business model that integrates clinical operations, data management, and global regulatory response into a single structure.
According to industry sources on the 28th, JNPMEDI's sales last year increased approximately 2.5 times compared to the previous year. Based on this trend, the company expects to maintain a high growth rate this year as well. Industry analysis suggests that the business structure itself has entered an expansion phase due to accumulated demand for the digital transformation of clinical trials, rather than the effect of a single project expansion or one-time orders.
Unlike existing contract research organizations (CROs) or simple clinical IT companies, JNPMEDI has built a structure that manages the entire clinical trial process as a single digital flow. The linking of the entire lifecycle—from the clinical trial planning stage to operation, data management, and response to regulatory submissions—is cited as a key differentiator. The company explained that it focused on structurally reducing the administrative burden and data management inefficiencies that repeatedly occur at clinical sites.
Its flagship solution, 'Maven Clinical Cloud,' focused on improving the limitations of data omission, error, and change history management that occurred in existing clinical trial environments that relied on paper documents and manual transcription. By applying electronic recording and management from the data generation stage and designing it to systematically track change history, it simultaneously increased data reliability and management efficiency.
Automation functions applied to the clinical trial process are also contributing to improved operational efficiency. By automatically designing data structures and consistently applying management rules based on clinical trial protocol standards, the company has reduced errors that may occur at the design stage and alleviated the burden of repetitive tasks. As a result, it is reported that cost reduction and the effect of shortening the clinical trial duration are appearing simultaneously.
Global regulatory response capability is also mentioned as a major competitive edge. The company has advanced its solutions by reflecting the data standards and submission requirements demanded by major regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Ministry of Food and Drug Safety (MFDS). In addition, it is expanding its scope of application in multi-national clinical trial environments by designing clinical data to be managed and converted in accordance with international standards.
An industry official stated, "In the global clinical trial environment, data management capabilities and regulatory response abilities are required simultaneously. There is a growing trend to attempt to integrate clinical operations, data, and regulatory response into a single platform."
Based on this business structure, JNPMEDI is accelerating its move into the global market. In particular, it plans to gradually increase the proportion of overseas projects by combining regulatory response consulting and clinical operation support, centered on the United States. The plan is to build a foundation for mid- to long-term growth by accumulating operational experience in markets with strict regulatory requirements.
A company official said, "The clinical trial environment is rapidly reorganizing around data and regulatory response. We will continue to improve the operational efficiency of domestic and international clinical sites through our integrated platform."